Dr. Drake is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
- Duke University HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 2003 - 2005
- Duke University HospitalResidency, Internal Medicine, 2001 - 2003
- Washington University in St. Louis School of MedicineClass of 2001
- Harvard UniversityA.B., Biology, Magna Cum Laude, 1989 - 1993
Certifications & Licensure
- MN State Medical License 2006 - 2025
- NC State Medical License 2001 - 2006
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- New Investigator Award, Department of Medicine Mayo Clinic, Rochester, MN, 2010
- Young Investigator Award American Society for Bone and Mineral Research, 2009
- Summa Cum Laude Thesis Harvard College, 1993
- Join now to see all
Publications & Presentations
PubMed
- 994 citationsBisphosphonates: Mechanism of Action and Role in Clinical PracticeMatthew T. Drake, Bart L. Clarke, Sundeep Khosla
Mayo Clinic Proceedings. 2008-09-01 - 105 citationsPharmacology of bisphosphonates.Serge Cremers, Matthew T. Drake, F. Hal Ebetino, John P. Bilezikian, R. Graham G. Russell
British Journal of Clinical Pharmacology. 2019-06-01 - 210 citationsEffects of Parathyroid Hormone Treatment on Circulating Sclerostin Levels in Postmenopausal WomenMatthew T. Drake, Bhuma Srinivasan, Ulrike I. Mödder, James M. Peterson, Louise K. McCready
The Journal of Clinical Endocrinology and Metabolism. 2010-11-01
Journal Articles
- Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphomaInwards DJ, Fishkin PA, LaPlant BR, Drake MT, Kurtin PJ, Nikcevich DA, Wender DB, Lair BS, Witzig TE, Ann Oncol, 7/1/2014
- Effects of suppression of follicle-stimulating hormone secretion on bone resorption markers in postmenopausal womenDrake MT, McCready LK, Hoey KA, Atkinson EJ, Khosla S, Obstet Gynecol Surv, 5/1/2011
- Corrigendum to "Circulating osteogenic cells: Characterization and relationship to rates of bone loss in postmenopausal women"Undale A, Srinivasan B, Drake M, McCready L, Atkinson E, Peterson J, Riggs BL, Amin S, Modder UI, Khosla S, Bone, 1/1/2011
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Controversies in Pharmaceutical Management of Osteoporosis TherapyDrake MT, American Association of Clinical Endocrinologists Annual Meeting, 5/1/2014
- Monoclonal Gammopathy Associated Bone LossDrake MT, Dresden University Medical Center, Dresden, Germany, 4/1/2014
- Bone loss in monoclonal gammopathy of undetermined significance.Drake MT, Advances in Mineral Metabolism Annual Meeting, 4/1/2014
- Join now to see all
Lectures
- Monoclonal Gammopathy of Undetermined Significance (MGUS): Indications for Pre-Diagnostic Testing, Subsequent Diagnoses, and Follow-up Practice2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Optimizing Bone Health in Multiple Myeloma.Atlanta, GA - 5/1/2014
- Monoclonal gammopathy-associated bone loss.10/1/2013
- Join now to see all
Press Mentions
- Antihypertensive Medication Use in Older Adults at Risk for Hip Fracture—ReplyOctober 22nd, 2019
- Side Effects of Bisphosphonates for OsteoporosisMay 29th, 2019
- Vitamin D: Not Just the Sunshine Vitamin AnymoreApril 12th, 2019
- Join now to see all
Grant Support
- Pathogenesis Of Monoclonal Gammopathy Bone DiseaseNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2010–2011
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: